Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Toni K. Choueiri(Harvard University), Masatoshi Eto(Kyushu University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Tomáš Büchler(Charles University), Naveen S. Basappa(University of Alberta), María José Méndez-Vidal(Hospital Universitario Reina Sofía), Sergei Tjulandin(National Medical Research Center of Cardiology), Se Hoon Park(Samsung Medical Center), Bohuslav Melichar(Palacký University Olomouc), Thomas E. Hutson(Texas Oncology), C. Alemany(Florida Hospital Cancer Institute), Bradley A. McGregor(Harvard University), Thomas Powles(Queen Mary University of London), Viktor Grünwald(Essen University Hospital), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Sun Young Rha(Yonsei University Health System), Evgeny Kopyltsov(State Healthcare Institution "Regional Clinical Oncological Dispensary"), Anil Kapoor(Juravinski Cancer Centre), Teresa Alonso Gordoa(Hospital Universitario Ramón y Cajal), Jeffrey C. Goh(Queensland University of Technology), Michael Staehler(Ludwig-Maximilians-Universität München), Jaime R. Merchan(University of Miami), Ran Xie(Eisai (United States)), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kalgi Mody(Eisai (United States)), Jodi A. McKenzie(Eisai (United States)), Camillo Porta(University of Bari Aldo Moro)
Cited by 161Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis